Scott Fettner - Concepedia

Author

Scott Fettner

Roche (Switzerland)

Also Known As

Scott Fettner, Scott H. Fettner

Publications

714

Citations

H-Index

Concepts

All Affiliations

Roche (Switzerland)La Roche College Roche (United Kingdom)Roche (United States)St James's University Hospital

About

Scott Fettner is an author at Roche (Switzerland) specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	342
2	Pharmacology	4	4	312
3	Biostatistics	1	1	30
4	Immunology	1	1	94
5	Pathology	1	1	30

Scott Fettner

Publications

700

Citations

H-Index

Page 1

	Year	Citations
The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition Ashok Rakhit, Michael Pantze, Scott Fettner, European Journal of Clinical Pharmacology Pharmacokinetic ModelingCyp3a4 InhibitionErlotinib PharmacokineticsMedicineVivo Metabolic Inhibition	2007	120
Phase I Trial of 40-kd Branched Pegylated Interferon Alfa-2a for Patients With Advanced Renal Cell Carcinoma Robert J. Motzer, Ashok Rakhit, Michelle S. Ginsberg, Journal of Clinical Oncology	2001	101
Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA Hisham Abdallah, Joy Hsu, Peng Lü, The Journal of Clinical Pharmacology ImmunologyPharmacotherapyImmunotherapyPharmacodynamic ModelingRheumatoid Disorder	2016	94
Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals Jie Ling, Scott Fettner, Bert L. Lum, Anti-Cancer Drugs	2008	86
Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: A dose-escalation study Chris Twelves, José Trigo, Robert H. Jones, European Journal of Cancer Dose-escalation StudyMetastatic Breast CancerOncologyBreast OncologyPharmacology	2008	52
Safety and Pharmacokinetic Characterization of Nacubactam, a Novel β-Lactamase Inhibitor, Alone and in Combination with Meropenem, in Healthy Volunteers Navita L. Mallalieu, Erica Winter, Scott Fettner, Antimicrobial Agents and Chemotherapy	2020	50
The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects Marta Hamilton, Julie Wolf, Daniel W. Drolet, Cancer Chemotherapy and Pharmacology Healthy SubjectsErlotinib PharmacokineticsPharmacological StudyMedicinePrototypical Cyp3a4 Inducer	2014	46
Phase I Evaluation of a 40-kDa Branched-Chain Long-Acting Pegylated IFN-α-2a With and Without Cytarabine in Patients with Chronic Myelogenous Leukemia Moshe Talpaz, Ashok Rakhit, Karen Rittweger, Clinical Cancer Research	2005	32
Characterization of AUCs from sparsely sampled populations in toxicology studies. Sudhakar M. Pai, Scott Fettner, Gerald Hajian, Pharmaceutical Research Predictive ToxicologyBioanalysisPathologyToxicology TestingToxicology	1996	30
Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis Xiaoping Zhang, Ya‐Chi Chen, Scott Fettner, International Journal of Clinical Pharmacology and Therapeutics	2013	25

Page 1